RxDoctor Payments Data

Elias Sharba, MD

Critical Care Medicine · Dearborn, MINPI 1558331447

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (55.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 80.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $3,713 and has fallen 93.3% since, to $249 in 2025. Among critical care medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,450in general payments, 2019–2025

Across 61 payments — averaging $89.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$314
  • AstraZeneca$250
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$178
  • Regeneron Healthcare Solutions, Inc.$148
  • Inspire Medical Systems, Inc.$88
  • plus $104 from 5 others

What the payments were for

  • Travel & lodging$98518%
  • Food & beverage$1,42626%
  • Education$3,03956%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,450 in reported general payments places this provider in the 90th percentile of 177 critical care medicine providers in Michigan.

See all critical care medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$199,534
Medicare patients
656
Services billed
1,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter155$157,785
Breo ElliptaFluticasone/Vilanterol75$37,121
Spiriva RespimatTiotropium Bromide37$23,448
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$18,319
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$16,704
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$10,647
Pulmicort FlexhalerBudesonide16$7,491
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$7,385
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$6,602
Incruse ElliptaUmeclidinium Bromide14$6,013
Albuterol Sulfate HfaAlbuterol Sulfate125$4,603
SymbicortBudesonide/Formoterol Fumarate14$4,602
Wixela InhubFluticasone Propion/Salmeterol13$2,645
Fluticasone Propionate81$1,621
Ventolin HfaAlbuterol Sulfate23$1,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$314$219,239260 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$27$34,09554 claims
AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort$250$28,79854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 critical care medicine providers in Michigan.

Other critical care medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →